| Literature DB >> 35558782 |
Ming Hu1, Xue-Qiong Yang1, Chuen-Ping Wan2, Bang-Yan Wang1, Hai-Yue Yin1, Li-Jiao Shi1, Ya-Mei Wu1, Ya-Bin Yang1, Hao Zhou1, Zhong-Tao Ding1.
Abstract
Eleven new polyketones named diaporthsins A-K (1-11) were isolated from the fermentation of Diaporthe sp. JC-J7. The chemical structures of compounds (1-11) were elucidated by spectroscopic methods including HRESIMS, 2DNMR, NMR and chemical methods. Compound 11 features an unusual acyclic polyketone-phenolic polyketone hybrid structure that integrates the characteristics of different fungal metabolites (cytosporone and multiplolide). Compound 3 was the only C12-polyketone obtained in this research. These new polyketones showed inhibitory activity on triglycerides (TG) in steatosis hepatocyte L-02 cells. Among them, compound 5 and (4E)-6,7,9-trihydroxydec-4-enoic acid displayed inhibitory activities on TG in steatotic L-02 cells with inhibition ratios of 26% and 21% at concentration of 5 μg mL-1; also, inhibition ratios of 8-O-acetylmultiplolide A and phomopsisporone A at concentration of 5 μg mL-1 were calculated to be about 24% and 16%, respectively, which were equivalent to the antihyperlipidemic activity of lovastatin. The preliminary structure-activity relationship indicated that acetyl at C-8 can increase the antihyperlipidemic activity of multiplolide A and the glycol ester and hydroxyl at C-6 can also increase the corresponding activity of diaporthsin B. This journal is © The Royal Society of Chemistry.Entities:
Year: 2018 PMID: 35558782 PMCID: PMC9091869 DOI: 10.1039/c8ra08822e
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1The structures of the new compounds isolated from Diaporthe sp. JC-J7.
13C NMR and 1H NMR data of compounds 1–3
| Pos. | 1 | 2 | Pos. | 3 | |||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| 1 | 175.0 | 1 | 181.4 | ||||
| 2 | 173.6 | 2.26(m) | 33.8 | 2 | 2.07 (m) | 37.4 | |
| 3 | 2.22 (m), 2.35 (m) | 36.9 | 2.20 (m) | 27.8 | 3 | 1.52 (m) | 25.6 |
| 4 | 2.24 (m), 2.37 (m) | 30.6 | 5.43 (m) | 131.1 | 4 | 1.30 (m) | 29.3 |
| 5 | 5.50 (m) | 132.6 | 5.43 (m) | 127.0 | 5 | 1.95 (m) | 32.1 |
| 6 | 5.40 (m) | 127.8 | 2.06 (m) | 40.6 | 6 | 5.39 (m) | 132.9 |
| 7 | 2.09 (m), 2.26 (m) | 39.0 | 3.63 (m) | 70.0 | 7 | 5.37 (m) | 125.9 |
| 8 | 3.95 (m) | 70.2 | 1.44 (m) | 44.5 | 8 | 2.06 (m) | 40.7 |
| 9 | 1.50 (d, | 41.0 | 3.83 (q, | 66.2 | 9 | 3.62 (m) | 70.2 |
| 10 | 5.01 (m) | 67.2 | 1.07 (d, | 22.2 | 10 | 1.48 (m) | 44.6 |
| 11 | 1.24 (d, | 20.3 | 11 | 3.84 (m) | 66.3 | ||
| 12 | 1.06 (d, | 22.2 | |||||
Fig. 2The key HMBC correlations of compound 1.
Fig. 3The key HMBC correlations of compound 2.
Fig. 4The key HMBC correlations of compound 3.
13C NMR and 1H NMR data of compounds 4–6
| Pos. | 4 | 5 | 6 | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| 1 | 173.2 | 173.6 | 172.0 | |||
| 2 | 2.30 (m) | 33.9 | 2.32 (t, | 33.6 | 2.34 (m) | 27.3 |
| 3 | 2.23 (m) | 27.7 | 2.24 (m) | 27.6 | 1.79 (m), 1.98 (m) | 22.5 |
| 4 | 5.42 (m) | 130.8 | 5.44 (m) | 130.8 | 3.80 (m) | 74.8 |
| 5 | 5.41 (m) | 127.3 | 5.41 (m) | 127.3 | 2.34 (m), 2.63 (m) | 39.2 |
| 6 | 2.06 (t, | 40.5 | 2.06 (t, | 40.5 | 208.1 | |
| 7 | 3.63 (m) | 70.0 | 3.63 (m) | 69.9 | 4.86 (d, | 76.0 |
| 8 | 1.44 (m) | 44.5 | 1.45 (m) | 44.6 | 2.06 (m), 2.20 (m) | 39.0 |
| 9 | 3.84 (q, | 66.2 | 3.83 (q, | 66.1 | 5.10 (m) | 66.7 |
| 10 | 1.06 (d, | 22.2 | 1.07 (d, | 22.2 | 1.12 (d, | 18.7 |
| 1′ | 1.08 (d, | 14.7 | 4.03 (t, | 65.5 | 170.7 | |
| 2′ | 4.67 (m) | 74.2 | 3.62 (t, | 59.6 | 2.20 (s) | 19.3 |
| 3′ | 3.66 (m) | 68.8 | ||||
| 4′ | 1.05 (d, | 17.5 | ||||
| OCH3 | 3.19 (s) | 55.2 | ||||
Fig. 5The key HMBC correlations of compound 4.
Fig. 6The key HMBC correlations of compound 5.
Fig. 7The key HMBC correlations of compound 6.
13C NMR and 1H NMR data of compounds 7–9
| Pos. | 7 | 8 | Pos. | 9 | |||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| 1 | 173.6 | 172.2 | 1 | 173.6 | |||
| 2 | 2.33 (m) | 33.4 | 4.52 (m) | 68.1 | 2 | 2.31 (m) | 34.0 |
| 3 | 2.27 (m) | 27.8 | 2.22 (m), 2.84 (m) | 45.6 | 3 | 2.26 (m) | 28.0 |
| 4 | 5.53 (m) | 131.1 | 4.52 (m) | 70.3 | 4 | 5.46 (m) | 132.4 |
| 5 | 5.51 (m) | 126.5 | 5.60 (m) | 129.7 | 5 | 5.40 (m) | 127.0 |
| 6 | 2.06 (m), 2.18 (m) | 39.0 | 5.50 (m) | 134.7 | 6 | 2.06 (m), 2.12 (m) | 41.3 |
| 7 | 3.56 (m) | 75.7 | 3.78 (m) | 73.8 | 7 | 3.76 (m) | 72.0 |
| 8 | 1.06 (m), 1.54 (m) | 37.9 | 1.03 (m), 2.43 (m) | 34.9 | 8 | 1.42 (m), 1.49(m) | 44.3 |
| 9 | 3.70 (m) | 71.8 | 4.95 (m) | 70.1 | 9 | 3.96 (m) | 68.8 |
| 10 | 1.13 (d, | 21.0 | 1.20 (d, | 17.5 | 10 | 1.13 (d, | 24.0 |
| 1′ | 4.66 (q, | 98.0 | OCH3 | 3.60 (s) | 51.6 | ||
| 2′ | 1.20 (d, | 20.6 | |||||
Fig. 8The key HMBC correlations of compound 7.
Fig. 9The key HMBC correlations of compound 8.
Fig. 10The key HMBC correlations of compound 9.
Fig. 11The key HMBC correlations of compound 10.
13C NMR and 1H NMR data of compounds 10–11
| Pos. | 10 | 11 | Pos. | 11 | |||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||
| 1 | 172.2 | 172.1 | 16 | 4.07 (t, | 64.2 | ||
| 2 | 2.33 (m) | 33.8 | 3.59 (s) | 39.1 | 17 | 173.7 | |
| 3 | 2.28 (m) | 27.8 | 135.6 | 18 | 2.41 (m), 2.36 (m) | 33.7 | |
| 4 | 5.50 (m) | 130.7 | 6.22 (d, | 110.3 | 19 | 2.32 (m) | 27.7 |
| 5 | 5.52 (m) | 127.7 | 159.9 | 20 | 5.54 (m) | 130.8 | |
| 6 | 2.13 (m) | 41.2 | 6.28 (d, | 101.4 | 21 | 5.51 (m) | 127.3 |
| 7 | 3.78 (m) | 71.2 | 158.4 | 22 | 2.17 (m) | 40.5 | |
| 8 | 1.42 (m), 1.54 (m) | 44.6 | 120.0 | 23 | 3.65 (m) | 70.0 | |
| 9 | 3.95 (m) | 67.3 | 207.6 | 24 | 1.51 (m) | 44.5 | |
| 10 | 1.12 (d, | 23.5 | 2.92 (t, | 43.7 | 25 | 3.90 (m) | 66.2 |
| 11 | 4.07 (q, | 59.6 | 1.64 (m) | 24.0 | 26 | 1.15 (d, | 22.3 |
| 12 | 1.20 (t, | 13.7 | 1.37 (s) | 28.2 | 27 | 4.13 (q, | 60.5 |
| 13 | 1.37 (s) | 28.2 | 28 | 1.29 (t, | 13.1 | ||
| 14 | 1.37 (s) | 25.5 | |||||
| 15 | 1.64 (m) | 28.9 | |||||
Fig. 12The key HMBC correlations of compound 11.
Antihyperlipidemic activities of these compounds at concentration of 5 μg mL−1
| Sample | TG concentration (mmol g−1) | Inhibition ratio |
|---|---|---|
| 5 | 0.307 | 26% |
| THEA | 0.326 | 21% |
| 8- | 0.312 | 24% |
| Phomopsisporone A | 0.332 | 16% |
| Lovastatin | 0.283 | 31% |
| Other compounds | <10% | |
| Control | 0.415 | |
| Normal | 0.015 |